ArticleScience translational medicine2025

Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models.

Xinyue Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.